Global Point of Care Diagnostics Market (POC Testing Market) Size, Share, Trends and Growth Forecast Report – Segmented By Product (Infectious Diseases, Cardiac Markers, Oncology Markers, OTC Diagnostic Tests, Drugs Of Abuse, Blood Gas Testing, Fertility Testing, Urinalysis, Coagulation, Hematology, Glucose Monitoring, Ambulatory Chemistry and Decentralized Clinical Chemistry) and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Industry Analysis (2024 to 2029)

Updated On: June, 2024
ID: 1480
Pages: 165

Global Point of Care Diagnostics Market Size (2024 to 2029)

As per our report, the global point of care (POC) diagnostics market size is estimated to be growing at 9.76% CAGR during the forecast period. The global POC testing market is predicted to grow to USD 47.82 billion by 2029 from USD 30.02 billion in 2024.

Point-of-care testing (POCT) is medical diagnostic testing at or near the point of care at the time and place of patient care. Point-of-care tests are simple medical tests that can be performed at the bedside. The driving notion behind POCT is to bring the test conveniently and immediately to the patient. It increases the likelihood that the patient, physician, and care team will receive the results quicker, allowing for better immediate clinical management decisions. Point-of-care diagnostics, also known as POC testing, is prevalent in enabling test results quickly and accurately. These are user-friendly, where one can take the decentralized healthcare industry trend, enabling remote patient care, early diagnosis, and cost savings.

The coupling of POCT devices and electronic healthcare records (EHR) enables test results to be shared instantly with care providers. Using mobile devices in the healthcare setting also allows the healthcare provider to access patient test results quickly from a POCT device. For instance, a reduction in morbidity and mortality has been associated with rapid turnaround times from a study using the i-STAT to analyze blood lactate levels after congenital heart surgery. POCT has become established worldwide and finds vital roles in public health. Potential operational benefits include more rapid decision-making and triage, reduced operating times, high dependency, postoperative care time, emergency room time, number of outpatient clinic visits, number of hospital beds required, ensuring optimal use of professional time, and reduced antimicrobial medication. Tests performed at the point of care allow for a more efficient workflow process. Rapid test results enable expeditious decision-making and treatment. Portable devices are used, which means less space is required, and there’s a lot of flexibility in moving the workspace.


The growing need for immediate test results and growing market penetration of EHR (Electronic Health Records) and PACS (Picture Archiving and Communication Systems) are majorly propelling the global point-of-care diagnostics market growth.

Adoption of sedentary lifestyles, unhealthy eating habits, and environmental factors are expected to surge the growth rate of the POC diagnostics market. Furthermore, the growing demand for more efficient, easy-to-use, and faster consumer devices and these portable personal care devices is fuelling the global POC testing market growth. In addition, new product launches of home-testing cancer kits at regular intervals and enhanced laboratories due to the integration of automation techniques in healthcare are estimated to boost market growth.

Increasing R&D activities to introduce new POC tests and devices for rapid disease detection and monitoring drives the progress of the point-of-care diagnostics market.

Recently in February 2018, Siemens Healthineers gained FDA approval (Food and Drug Administration) for total carbon dioxide (TCO2) and blood urea nitrogen (BUN) POC testing, increasing its market presence. The high prevalence of chronic illnesses and cancers means that a large customer base deploys cheap and instant diagnostic tests, driving the point-of-care diagnostics /testing market. It is complemented by several cheap initiatives to facilitate POC tests in diagnostic and screening procedures.


Lack of skilled people in manufacturing the kits with the latest design in some regions is a significant restraint to the global POC diagnostics market growth.

In addition, the cost is a roadblock factor, as laboratory testing tends to be less expensive than POC testing. Providers typically require the support of a laboratory to meet quality and accreditation requirements. Quality assurance can be rigorous testing performed by clinical staff rather than individuals who have been laboratory trained. Errors could arise if the team does not understand the importance of quality control and quality assurance practices.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Product, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Market Players

Abbott Laboratories, Inc., Danaher Corporation, Roche Diagnostics Limited, BioMerieux, Siemens Healthcare, Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., and PTS Diagnostics.



Global Point of Care Diagnostics Market Analysis By Product

The glucose monitoring segment led the market with a significant share in 2023 due to factors such as increasing the adoption rate of portable glucose meters with each passing year and growing awareness among diabetic patients to monitor glucose levels in the blood at regular intervals.

The cancer markers market segment is to grow at a high pace. The oncology makers segment is another lucrative segment among all and is anticipated to register a healthy CAGR during the forecast period owing to an increase in cancer cases and increasing death of cancer due to the delay in the identification of cancer in the body. Early detection of tumors can provide a more effective treatment for the tumor patient. Point-of-care (POC) testing is used for the patient to get the result in a short period with less cost. However, these patients must need further diagnosis if the tumor is detected in this POC testing by increasing advancement in using biomarkers in POC devices to know cancer in the patient more accurately.

The cardiac maker segment is also expected to perform well during the global POPC testing market forecast period during the foreseen years. Hospitals are increasingly using rapid results for cardiac-based devices to measure cardiac biomarkers. Some groups, such as the U.K. National Institute for Health and Care Excellence and the European Society of Cardiology, have accepted similar decision-making protocols for rapidly measuring cardiac troponin. Patients suffering from chest pain undergo these tests to know the quick result of their heart condition.

Global Point of Care Diagnostics Market Analysis By End-User

The clinic segment dominated the market, contributing a significant share of the worldwide market based on end-users. Moreover, it is to grow further during the forecast period due to market-boosting factors like the availability of portable POC devices, government initiatives, differentiation of healthcare services in different regions, and a rise in the number of CLIA-approved tests to diagnose various disorders.

The home healthcare segment is contributing a significant share of the market. It is likely to increase during the forecast period due to the emergence of economical and mobile POC testing devices and increasing demand for POC in home settings. In addition, it offers a high level of comfort to the patients.


The North American region is the leader in accounting for the highest global POC testing market share. In 2020, the North American market was worth USD 8340 Million, and it will continue the growing trends in the years to come. Unhealthy lifestyles, a high number of chronic diseases, a rising number of FDA approvals, and government regulations related to healthcare development are the key drivers behind the growth of POC diagnostics in North America. Canada shares the largest area in this region due to increased advanced point-of-care diagnostics and people caring more about their health. In Canada, scientists at the National Microbiology Laboratory (NML) are working to support providing point-of-care (POC) diagnostic testing devices for all levels of people at an affordable price. These POC devices are used mostly for tuberculosis, chlamydia, HIV, meningitis, and gastrointestinal diseases in this area. In 2020, the Pan-Canadian COVID-19 testing and screening guide different types of testing technologies using point-of-care diagnosis. Health Canada also gets approval from the U.S. Food and Drug Administration (FDA) for point-of-care testing and self-testing kits.

The market in Asia-Pacific is anticipated to grow at a CAGR of 10.2% during the forecast period. In the Asia Pacific, the market is expanding due to the rising prevalence of strategic initiatives taken by international players to improve healthcare infrastructure and increase awareness in developing countries. In the Asia-Pacific region, the market is expanding due to the rising prevalence of strategic initiatives taken by international players to improve healthcare infrastructure. In India, the Point-of-care diagnostics device market is increasing due to the use of these devices in monitoring ECG, oxygen saturation, blood pressure, and temperature, and increasing advanced POC devices. Key players, such as Siemens, Roche, and Abbot, are increasing investment in manufacturing POC diagnostic devices for homes, clinics, and hospitals. These manufacturers are producing portable, easy-to-use, affordable devices for people's convenience. Indian scientists and entrepreneurs have made more effort to develop next-generation POC diagnostic devices based on the latest technologies, such as smartphones and cloud-based devices. Researchers are going on a cancer diagnosis which high people are suffering in India. Nano biosensors are an excellent material for highly sensitive point-of-care (POC) cancer diagnostics. In China, the point of care (POC) market has started growing during the coronavirus period due to the focus of the healthcare system on in vitro diagnostics (IVD) and imaging testing. China is one of the largest manufacturers of these products and exports them to various countries. Government hospitals also use diagnostics. In China, the point of care (POC) market has started growing during the coronavirus period due to the healthcare system's focus on in vitro diagnostic (IVD). China is one of the largest manufacturers of these products and exports them to various countries. Government hospitals also use diagnostics tests to reduce the spread of the virus. In China, screening campaigns on targeted diseases such as HPV, prenatally evident conditions, hepatitis, and infectious emerging diseases such as avian flu and drug-resistant tuberculosis use these rapid POC tests to increase the market demand in this region.

Europe has a share of 32% due to viruses, increased adoption of advanced Point of care diagnostic devices, and increased awareness about innovative and advanced Point of care diagnostic devices. In recent years in Europe, diagnosing infectious diseases has increased to provide treatment in a timely manner. By using this point-of-care testing, infectious diseases can be identified quickly and controlled in a short period. In Europe, this point-of-care testing is used mainly during the pandemic time. In Europe, most infectious diseases such as influenza and HIV undergo point-of-care testing rapidly to detect the infection in the person in less time. Due to increases in the number of migrants in these regions, malaria is common. Therefore, more Europeans traveling to and from these nations may have impacted POCT for malaria. European Commission proposed using POCT for COVID-19 testing for the primary screening purpose. POCT's techniques include faster diagnosis times, improved hospital flow, and higher testing rates.


Notable market participants in the Global Point of Care Diagnostics Market profiled Abbott Laboratories, Inc., Danaher Corporation, Roche Diagnostics Limited, BioMerieux, Siemens Healthcare, Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., and PTS Diagnostics. Key market players are investing more in R&D to develop innovative products and expand revenues through collaborations with other companies, research universities, and private research organizations.

Siemens Healthineers, one of the leading companies in the POC diagnostics market, presents its customizable products for in vitro diagnostic tests designed to improve workflow, efficiency, and clinical outcomes. The company offers the latest innovations in Central Laboratories' Atellica® solutions, blood gas testing during treatment, and molecular diagnostics. The RAPIDPoint® 500e Blood Gas System2 provides an improved user experience and sets a higher standard for healthcare simplicity, quality, and data security. For labs interested in expanding the reach of molecular diagnostics, the new Fast Track Diagnostics test menu from Siemens Healthineers provides a syndrome panel to improve patient care and workflow.


  • In 2022, An agreement was announced between Una Health and MedTech, Siemens Healthineers for the distribution of Atellica VTLi Patient-side Immunoassay Analyser in primary care in the U.K. Una Health is high in manufacturing innovative point-of-care diagnostics and the improvement of the patient in healthcare settings.
  • The Cobas Pulse System, Roche's newest generation of connected point-of-care solutions for advanced blood glucose monitoring, was launched in 2022. This system helps the high performance and smartphone usability of blood glucose meters.
  • In 2022, Siemens Healthineers manufactured a CLINITEST Rapid COVID-19 Antigen Self-Test, approved by U.S. Food and Drug Administration for access at home.


This market research report on the global point-of-care diagnostics market (POC testing market) has been segmented and sub-segmented based on the product, end-user, and region.

By Product

  • Infectious Diseases
  • Cardiac Markers
  • Oncology Markers
  • OTC Diagnostic Tests
  • Drugs Of Abuse
  • Blood Gas Testing
  • Fertility Testing
  • Urinalysis
  • Coagulation
  • Hematology
  • Glucose Monitoring
  • Ambulatory Chemistry
  • Decentralized Clinical Chemistry

By End-User

  • Clinics
  • Hospitals
  • Home Healthcare
  • Ambulatory Care Settings
  • Laboratories

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

Which factors contribute to the growth of point of care diagnostics in Europe?

Factors such as the increasing prevalence of chronic diseases and the demand for rapid diagnostics contribute to the growth of point-of-care diagnostics market in Europe.

What are the emerging trends in Point of Care diagnostics in the Middle East and Africa?

The Middle East and Africa are witnessing a trend towards decentralized healthcare, driving the adoption of Point of Care diagnostics for quicker and more accessible medical results.

What are the challenges faced by Point of Care diagnostics companies in South America?

Challenges include navigating complex regulatory landscapes and addressing affordability concerns, which impact market penetration in South America.

How is the Point of Care diagnostics market in the Asia-Pacific region adapting to the increasing demand for personalized medicine?

The market is witnessing a shift towards the development of Point of Care diagnostics tailored for personalized medicine, reflecting the growing demand for individualized healthcare in the Asia-Pacific region.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample